Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14328006 | 0.82 | DRD2 (0.52) | DRD2DRD4DRD3MAPTALDH1A1 | |
| SCHEMBL4611909 | 0.80 | DRD2 (0.53) | DRD2DRD4DRD3MAPTALDH1A1 | |
| SCHEMBL29349920 | 0.80 | DRD2 (0.53) | DRD2DRD4DRD3MAPTALDH1A1 | |
| SCHEMBL16368719 | 0.79 | CYP4F2 (0.51) | DRD2DRD4DRD3LMNA | |
| SCHEMBL9854724 | 0.79 | KCNA3 (0.52) | DRD2DRD4DRD3ALDH1A1PKM | |
| SCHEMBL11292187 | 0.78 | KCNH2 (0.61) | DRD2DRD4DRD3MAPTALDH1A1 | |
| SCHEMBL9854722 | 0.78 | MPO (0.51) | MAPTGAALMNA | |
| SCHEMBL5286113 | 0.77 | DRD2 (0.73) | DRD2DRD4DRD3MAPTALDH1A1 | |
| SCHEMBL6228523 | 0.77 | MAPT (0.65) | DRD2DRD4DRD3MAPTALDH1A1 | |
| SCHEMBL22529979 | 0.77 | MAPT (0.53) | DRD2DRD4DRD3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| WO-2013093320-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | ARG1, TYR, NOS1 | DRD2 1253/4885DRD4 762/4885DRD3 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.